{"id":"W4392626511","doi":"10.1093/rheumatology/keae150","title":"Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis","year":2024,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network; Mount Sinai Hospital; Western University","funders":"Chugai Pharmaceutical; Cilag; Italfarmaco; Mitsubishi Tanabe Pharma Corporation; Astellas Foundation for Research on Metabolic Disorders; Otsuka Pharmaceutical; BERLIN-CHEMIE; Medac; Fonds Wetenschappelijk Onderzoek; Seagen; Argenx; Galápagos; Genentech; Vlaamse regering; Horizon Therapeutics; Nippon Shinyaku; AbbVie; Glenmark Pharmaceuticals; Acceleron; Eli Lilly Japan; Immune Tolerance Network; Alexion Pharmaceuticals; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Sanofi; Merck; GlaxoSmithKline; Amgen; Actelion Pharmaceuticals; Pfizer; Astellas Pharma; Eisai; Ikaria; CSL Behring; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Riociguat; Medicine; Placebo; Biomarker; Scleroderma (fungus); Internal medicine; Randomized controlled trial; Systemic scleroderma; Oncology; Disease; Pathology; Chronic thromboembolic pulmonary hypertension; Pulmonary hypertension","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003379208,0.001560194,0.004018753,0.0004286197,0.0002888206,0.001077065,0.0006026711,0.001369819,0.00571041],"category_scores_gemma":[0.002399982,0.0005309881,0.001689813,0.0004707962,0.0006194164,0.0006019667,0.0003332715,0.00195499,0.0006559347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005779535,"about_ca_system_score_gemma":0.0007890926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003609505,"about_ca_topic_score_gemma":0.0009239897,"domain_scores_codex":[0.9986711,0.0007705581,0.0000732008,0.0002079942,0.0001446767,0.0001325766],"domain_scores_gemma":[0.9987893,0.0003087962,0.0004169773,0.0001147412,0.0001350691,0.0002352599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9679165,0.002402458,0.001714922,0.0009015616,0.002516867,0.00003524904,0.00002565055,0.0002962897,0.007142121,0.00006185938,0.0006815466,0.01630494],"study_design_scores_gemma":[0.8741421,0.1056429,0.01399614,0.00007021195,0.003016841,0.00008222563,0.00001960408,0.0003935093,0.001149614,0.0001317396,0.001331728,0.00002344416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731759,0.01735188,0.001022215,0.0008139294,0.0003404796,0.003191106,0.002137355,0.0002000172,0.001767056],"genre_scores_gemma":[0.9860167,0.003349016,0.001848156,0.001026039,0.0003042525,0.003564134,0.002233658,0.00002656957,0.001631645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00571041,"threshold_uncertainty_score":0.01910329,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02121202080300695,"score_gpt":0.2743435909973963,"score_spread":0.2531315701943894,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}